These findings suggest that discrimination of interpatient differences in RAS in combination with BRAF V600E and TERT promoter variants could facilitate cytology examinations in preoperative precision malignancy diagnosis among patients with thyroid nodules. Here, BRAF is linked to thyroid nodule.